‘Totality, Not Piecemeal’: US Federal Circuit Revives Hikma Vascepa Skinny-Label Suit

Reading Hikma’s press releases and other public documents made it “at least plausible” that a physician would look to prescribe Hikma’s generic Vascepa product for any of its indications, including the highly-valued, patent-protected cardiovascular indication, the US Federal Circuit decided, reopening a lawsuit against the generics firm.